Matinas BioPharma (MTNB) Sees Unusually-High Trading Volume

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) saw strong trading volume on Thursday . 2,250,191 shares changed hands during trading, an increase of 168% from the previous session’s volume of 840,242 shares.The stock last traded at $0.87 and had previously closed at $0.76.

Separately, Maxim Group boosted their target price on Matinas BioPharma from $2.00 to $5.00 and gave the company a “buy” rating in a research report on Monday, November 12th.

Matinas BioPharma (NYSEAMERICAN:MTNB) last posted its quarterly earnings results on Monday, November 12th. The company reported ($0.03) earnings per share for the quarter.

Large investors have recently modified their holdings of the stock. Paloma Partners Management Co raised its stake in Matinas BioPharma by 1,724.7% in the second quarter. Paloma Partners Management Co now owns 317,499 shares of the company’s stock worth $138,000 after buying an additional 300,099 shares in the last quarter. K.J. Harrison & Partners Inc bought a new position in Matinas BioPharma in the third quarter worth approximately $150,000. Finally, Renaissance Technologies LLC raised its stake in Matinas BioPharma by 325.6% in the third quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock worth $124,000 after buying an additional 103,200 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by PressOracle and is the sole property of of PressOracle. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at

About Matinas BioPharma (NYSEAMERICAN:MTNB)

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

See Also: How to read a candlestick chart

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with's FREE daily email newsletter.

Leave a Reply

Leave a Reply